GE HealthCare Technologies : 43rd Annual J.P. Morgan Healthcare Conference Presentation - January 2025

Published: 2025-01-15 13:01:04 ET GEHC

43rd Annual J.P. Morgan Healthcare Conference

January 14, 2025

Create a world where healthcare has no limits

GE HealthCare and Sutter Health's long-term strategic collaboration

One of GE HealthCare's largest ever enterprise strategic partnerships. Sutter Health will invest $1B+ over 7 years for technology, solutions and service.

Benefiting 3.5 million patients across California

Delivering end-to-end, holistic portfolio. Integrates our D3 strategy and service solutions, enabling caregivers to provide more advanced care for patients, including in ambulatory settings.

Enabling precise, high-quality patient care from early screening to diagnosis to treatment to monitoring across multiple care areas

Aligning on creative problem-solving that goes beyond selling equipment to deliver sustainable solutions and predictability

GE HealthCare has contracted over 120 big deals worth over $5B since the spin-off

Our business segments by the numbers

Delivered >45% of recurring sales in 2023

Care journey, AI and digital innovation driving future growth

Imaging

Advanced Visualization

Patient Care

Pharmaceutical

Solutions (AVS)

Solutions (PCS)

Diagnostics (PDx)

Revenue(1)

$8.9B

$5.1B

$3.1B

$2.3B

EBIT margin(1)

9.2%

22.1%

12.2%

26.8%

$90 billion

market in 2023(2)

$110+ billion

Estimated by 2028(2)

Estimated total addressable

(1)

For the year 2023; Results recast in line with move of Image Guided Therapies from Imaging to Advanced

Visualization Solutions

(2)

Based on GE HealthCare estimates and Signify Research for digital solutions

Executing on our strategy

Developing leadership products to drive organic growth

Optimizing our business for margin expansion

Delivering precision care in key growth areas

Expanding recurring revenue through new models and M&A

Leadership product pipeline resulting from increased R&D commitment

Segment /

Digital

Innovation

2025

2026

2027

2028

Next Gen Mammography

Imaging

Next Gen MR

Total Body PET

Photon Counting CT

General Imaging - ULS

Women's Health - ULS

AVS

Cardiovascular - ULS

Next Gen Interventional solutions

Next Gen Interventional Cardiology

Next Gen Neuro Vascular Lab

Next Gen OR solutions

PCS

Next Gen Labor and Delivery solutions

Next Gen Portrait Mobile

Advanced Monitoring solutions

Flyrcado (Cardio)

PDx

Dopamine Transporter PET (Neuro)

FAPI (Oncology)

Digital/AI

Care Intellect for Oncology

Command Center 2.0

Cloud-enabled

Agentic AI

Theranostics clinical support

2025-2026 significant NPIs expected to help drive 1% to 2% of revenue growth over medium-term

Illustrates expected contribution to revenue; typically takes ~1 year post-launch for meaningful contribution to sales Anticipated product launch; visual is illustrative, product launch does not signify exact timing

Leadership product pipeline: Molecular Imaging

Oncology

Neurology

Cardiology

Helping providers with existing diagnostic agents today…

•

$7B market growing

10-12%+ CAGR(1)

•

High-value diagnostics

Cerianna

Metastatic breast cancer (MBC)

AdreView

Metastatic pheochromocytoma

or neuroblastoma

DaTscan

Parkinson's disease

Vizamyl

Alzheimer's disease

Rapiscan

Coronary artery disease

Myoview

Coronary artery disease

supporting precision care

… and diagnostic agents in development for tomorrow.(2)

•

Rapidly growing field of

Theranostics to target and

treat disease

•

Positive U.S. reimbursement

[18F]FAPI-74

[68Ga]FAPI-46

CAFs*

Phase II

CD8

HER2

Immuno-oncology

MBC

Phase I

LBT-999

Parkinson's disease

Phase III

Flyrcado

Flurpiridaz 18F

Coronary artery disease

landscape driving utilization

Cyclotrons │ FastLab │ Omni Legend PET/CT │ SIGNA PET/MR │ StarGuide SPECT/CT

Digital solutions

Quantitation, decision support, workflow management and MIM Software for imaging fusion, analytics and dosimetry

Innovating solutions to cover the breadth of steps throughout the patient journey

Not all products are available in all markets

(1)

GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024-2028

(2)

Being investigated for potential application. With the exception of Flyrcado, these products are investigational and have not

been approved in any country

* Cancer Associated Fibroblast

Targeting MSD Organic revenue growth* over the medium-term

100-200 bps

MSD (4%-6%)

50-80 bps

150-200 bps

Innovation

Commercial execution

Developing leadership products

•

Increasing pace of NPIs

• Enterprise selling strategy

•

Upgrading product portfolio

•

Simplifying SKU/Geo

Recurring revenue

•

Gaining market share

•

Growing software capabilities

•

Services expansion

•

PDx mix

Market normalization

• Improved China market

FY24E Organic

Market

Business

Precision care &

Medium-term target*

revenue growth*

normalization

optimization

growth acceleration

2026-2028

Organic revenue growth* driven by multiple upside opportunities

* Non-GAAP financial measure. See appendix for more information on our Outlook

Optimizing our business for margin expansion

Platforming

Variable cost

Organizational

productivity

simplification

Structural

optimization

Strong progress on lean initiatives driving customer efficiencies and supporting solid margin expansion

Expanding Adjusted EBIT margin* through focused actions

80-120 bps

(150-250) bps

200-300 bps

High-teens

to 20%+

G&A

150-250 bps

optimization

Investments

•

Organizational

•

R&D

Net

•

simplification

•

S&M

Productivity

Structural

Optimization

Growth &

•

Product

14.5%

Innovation

platforming

•

Variable cost

•

NPIs at higher

Progress

productivity

gross margin

since spin

•

Enterprise selling

strategy

•

Strategic pricing

2022 standalone

2024E Adjusted

Gross margin

Operating expense Medium-term target*

Adjusted EBIT margin*

EBIT margin*

2026-2028

Excellent progress on Adjusted EBIT margin* expansion, tracking ahead of initial expectations

Disclaimer

GE HealthCare Technologies Inc. published this content on January 15, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 15, 2025 at 18:00:03.711.